Literature DB >> 24921210

Cirrhosis regression in patients with viral hepatitis B and C: a systematic review.

Vignan Manne1, Ehsaan Akhtar, Sammy Saab.   

Abstract

INTRODUCTION: Cirrhosis is a major milestone in patients with chronic liver disease because of its impact on patient morbidity and mortality. Chronic hepatitis B (CHB) and hepatitis C (CHC) are important causes of cirrhosis. This systematic review examines the relevant literature and evidence to assess whether cirrhosis can be reversible in patients with cirrhosis from viral hepatitis through long viral suppression.
METHODS: A MEDLINE and Cochrane Library search was conducted to identify all articles pertinent to the subject matter. Fourteen publications were included in the final analysis: 4 hepatitis B studies and 10 hepatitis C studies. Data abstracted from individual studies included patient demographics, antiviral therapy used, length of treatment, liver biopsy scoring system, length of biopsy, and time between biopsies.
RESULTS: In CHB, the 7 studies reviewed included a total of 463 cirrhotic patients. Regression of cirrhosis was noted in a median of 70% (range, 33% to 80%) of patients. In CHC, the 13 studies reviewed included a total of 58 cirrhotic patients. Regression of cirrhosis was seen in a median of 64% (range, 33% to 100%) of patients with sustained viral response.
CONCLUSIONS: The results of our review suggest that viral suppression in CHB and sustained virologic response in CHC can be associated with histologic regression of cirrhosis in select patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24921210     DOI: 10.1097/MCG.0000000000000162

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

Review 1.  Future therapy of portal hypertension in liver cirrhosis - a guess.

Authors:  Tilman Sauerbruch; Jonel Trebicka
Journal:  F1000Prime Rep       Date:  2014-10-01

Review 2.  Liver-related effects of chronic hepatitis C antiviral treatment.

Authors:  Tea L Laursen; Thomas D Sandahl; Konstantin Kazankov; Jacob George; Henning Grønbæk
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

3.  Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.

Authors:  Christine E Orr; Peter L Wang; Lina Chen; Tao Wang
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.240

4.  Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats.

Authors:  Luciano Sobrevals; Mónica Enguita; Jorge Quiroga; Jesús Prieto; Puri Fortes
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

5.  Human fibroblast growth factor-21 serves as a predictor and prognostic factor in patients with hepatitis B cirrhosis combined with adrenal insufficiency.

Authors:  Jian Zhang; Junhong Li; Junwei Ma; Hongxin Wang; Yin Yi
Journal:  Exp Ther Med       Date:  2018-02-06       Impact factor: 2.447

Review 6.  Cigarette Smoke Particle-Induced Lung Injury and Iron Homeostasis.

Authors:  Andrew J Ghio; Elizabeth N Pavlisko; Victor L Roggli; Nevins W Todd; Rahul G Sangani
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-01-12

Review 7.  Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review.

Authors:  Shahbaz Khan; Romil Saxena
Journal:  Adv Anat Pathol       Date:  2021-11-01       Impact factor: 3.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.